IRIS Accounts Production v25.1.4.42 15331206 Board of Directors 6.12.23 31.12.24 31.12.24 26.6.25 false true false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh153312062023-12-05153312062024-12-31153312062023-12-062024-12-31153312062023-12-0515331206ns15:EnglandWales2023-12-062024-12-3115331206ns14:PoundSterling2023-12-062024-12-3115331206ns10:Director12023-12-062024-12-3115331206ns10:PrivateLimitedCompanyLtd2023-12-062024-12-3115331206ns10:SmallEntities2023-12-062024-12-3115331206ns10:Audited2023-12-062024-12-3115331206ns10:SmallCompaniesRegimeForDirectorsReport2023-12-062024-12-3115331206ns10:SmallCompaniesRegimeForAccounts2023-12-062024-12-3115331206ns10:FullAccounts2023-12-062024-12-3115331206ns10:Director22023-12-062024-12-3115331206ns10:Director32023-12-062024-12-3115331206ns10:RegisteredOffice2023-12-062024-12-3115331206ns5:CurrentFinancialInstruments2024-12-3115331206ns5:ShareCapital2024-12-3115331206ns5:RetainedEarningsAccumulatedLosses2024-12-3115331206ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-31
REGISTERED NUMBER: 15331206 (England and Wales)










FINANCIAL STATEMENTS

FOR THE PERIOD

6 DECEMBER 2023 TO 31 DECEMBER 2024

FOR

MARENGO THERAPEUTICS LIMITED

MARENGO THERAPEUTICS LIMITED (REGISTERED NUMBER: 15331206)






CONTENTS OF THE FINANCIAL STATEMENTS
for the Period 6 DECEMBER 2023 TO 31 DECEMBER 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


MARENGO THERAPEUTICS LIMITED

COMPANY INFORMATION
for the Period 6 DECEMBER 2023 TO 31 DECEMBER 2024







DIRECTORS: A Bayliffe
Ms S N Makhni
Z Su



REGISTERED OFFICE: Five Ways
57/59 Hatfield Road
Potters Bar
Hertfordshire
EN6 1HS



REGISTERED NUMBER: 15331206 (England and Wales)



SENIOR STATUTORY
AUDITOR:
Mr Tim John Newman FCCA



AUDITORS: SRG Newmans Limited
Accountants and Statutory Auditors
Five Ways
57-59 Hatfield Road
Potters Bar
Hertfordshire
EN6 1HS

MARENGO THERAPEUTICS LIMITED (REGISTERED NUMBER: 15331206)

BALANCE SHEET
31 DECEMBER 2024

Notes £   
CURRENT ASSETS
Debtors 5 2,592
Cash at bank 11,188
13,780
CREDITORS
Amounts falling due within one year 6 163,254
NET CURRENT LIABILITIES (149,474 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(149,474

)

CAPITAL AND RESERVES
Called up share capital 100
Retained earnings (149,574 )
(149,474 )

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 26 June 2025 and were signed on its behalf by:





Ms S N Makhni - Director


MARENGO THERAPEUTICS LIMITED (REGISTERED NUMBER: 15331206)

NOTES TO THE FINANCIAL STATEMENTS
for the Period 6 DECEMBER 2023 TO 31 DECEMBER 2024

1. STATUTORY INFORMATION

Marengo Therapeutics Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern
Notwithstanding the net liabilities on the balance sheet of £149,574, the Directors of Marengo Therapeutics Limited are satisfied that the accounts should be prepared on a going concern basis. They have received assurances from Marengo Therapeutics, Inc. (the ultimate parent company of Marengo Therapeutics Limited), that there are sufficient funds in place for at least 12 months from the signing of the accounts and that they will continue to support Marengo Therapeutics Limited for at least 12 months from the date of approval of these financial statements to enable the company to continue to trade.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

MARENGO THERAPEUTICS LIMITED (REGISTERED NUMBER: 15331206)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Period 6 DECEMBER 2023 TO 31 DECEMBER 2024

2. ACCOUNTING POLICIES - continued

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 1 .

4. AUDITORS' REMUNERATION
£   
Fees payable to the company's auditors for the audit of the
company's financial statements

17,400

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Other debtors 2,592

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Taxation and social security 73
Other creditors 163,181
163,254

7. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Mr Tim John Newman FCCA (Senior Statutory Auditor)
for and on behalf of SRG Newmans Limited

8. RELATED PARTY DISCLOSURES

During the year, the company received £405,978 in management charges from Marengo Therapeutics Inc., the ultimate controlling party.

9. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is Marengo Therapeutics, Inc. by virtue of its shareholding.